Despite the approval of novel oral anticoagulants in recent years, nearly 90 percent of atrial fibrillation patients with ischemic stroke or transient ischemic attack receive warfarin, according to analysis of patients hospitalized between October 2010 and September 2012.

Is MACRA the new SGR? Thankfully not. But that doesn’t mean you can ignore it.

Patients who take proton pump inhibitors (PPIs) may be at an increased risk for myocardial infarction (MI) and other cardiovascular outcomes, according to a data mining analysis. However, there was no association between the use of H2 blockers and MI or cardiovascular risk. H2 blockers are alternatives to PPIs in treating gastroesophageal reflux disease.

If the alliance between his health system in Texas and the Cleveland Clinic didn’t bring a single new patient through their doors, it would still be a victory, said Michael Mack, MD. “We’ve already received enough value that we view this as a success.”

An FDA advisory panel on June 10 recommended the approval of evolocumab, a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor intended to reduce low-density lipoprotein cholesterol and improve other lipids.

An analysis of a large, nationwide registry of patients with atrial fibrillation has delivered some counterintuitive results that could signal a needed change in healthcare utilization for such patients.

The FDA’s advisory panel voted 13-3 in favor of alirocumab as an anticholesterol treatment, paving the way for what might become the first fully human monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) in the U.S.

A New York medical center paid almost $19 million to settle a kickback case involving a cardiology practice. The charges alleged that the medical center improperly paid the practice for referrals and improperly submitted cost reports for cardiology fellows’ services.